PMVP Stock — PMV Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.23

Market cap

$92.9M

Cash

$108.5M

Enterprise value

-$15.6M

Balance sheet

Cash	$108.5M
Debt	$0.0M
Net cash	$108.5M
Enterprise value	-$15.6M
Basic shares	53.5M shares
Fully diluted shares	70.3M shares
Fully diluted market cap	$86.5M
Cash per share	$2.03
Quarterly burn	$14.6M
Cash runway	5.4 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

53.5M

Pre-funded warrants

0.0M

Options

15.8M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.0M

FDSO

70.3M

Cap table as of 2026-06-30.

Price history

Loading PMVP daily closes…

Loading price history…

Next catalyst

rezatapopt · Est. Feb 14, 2027 · quarter midpoint · guided in 7 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Feb 14, 2027 in 7 wks quarter midpoint	rezatapopt accelerated-approval NDA submission for platinum-resistant/refractory ovarian cancer	Not disclosed	platinum-resistant/refractory ovarian cancer	Q1 2027
Jan 26 - Mar 9 in 11 wks	rezatapopt	Phase 1/2	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer	—
Apr 12 - May 24 in 5 mo	metformin hydrochloride 500 mg tablet	Phase 1	TP53 Y220C Mutation; Advanced Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Rezatapopt

Phase 2 · Active Modality: small molecule (oral)

Target mutant p53 (Y220C)

Indications

ovarian cancer (platinum-resistant/refractory, TP53 Y220C) (Phase 2)
solid tumors (TP53 Y220C, tumor-agnostic) (Phase 2)

Catalysts

— first quarter of 2027

Status note Lead candidate: orally available small molecule that structurally corrects mutant p53 with the Y220C mutation. PYNNACLE Phase 1/2; single-arm Phase 2 registrational portion (dosed since Q1 2024) intended as pivotal. FDA Fast Track (October 2020) and Orphan Drug Designation (March 2026, for TP53 Y220C ovarian/fallopian tube/peritoneal cancer). Note: going-concern doubt disclosed — cash may not fund operations for one year from this report. Other p53 programs undescribed as distinct candidates.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	rezatapopt
Lead indication	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer
Lead phase	Phase 1/2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04585750	Phase 1/2	Recruiting	Sponsor	PMV Pharmaceuticals, Inc	MRK	Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer	—
NCT07372625	Phase 1	Recruiting	Sponsor	PMV Pharmaceuticals, Inc	—	TP53 Y220C Mutation; Advanced Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for PMV Pharmaceuticals, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	4,245,085	no change	0.26%	2026-08-14
Stonepine Capital	536,086	-172,016	0.55%	2026-08-17
ADAR1 Capital Management	201,008	-30,000	0.01%	2026-08-14
Ikarian Capital	89,136	no change	0.02%	2026-08-14
Deerfield Management	8,790	no change	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PMVP — PMV Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

PMVP — PMV Pharmaceuticals Inc.